Stock fact sheet · data as of
BioMarin Pharmaceutical Inc. (BMRN): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · High Growth
Is BMRN undervalued?
At 56.05 (close of 16 Oct 2026), BMRN trades 126% over the GLS average fair value of 24.83, with 1 of 8 models above the price. The stock earns none of the Wheel Score's Value points at this price. That is a statement about price against trailing fundamentals, not about the company's prospects - the Wall Street View and the Growth tab on the Quote page carry the forward numbers.
There is a wide gap between EPV (4.20) and 10 Cap (87.72). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files BMRN under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for BMRN
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 6.74 | -88% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 16.70 | -70% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 16.05 | -71% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 6.60 | -88% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 23.15 | -59% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 87.72 | +56% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 37.44 | -33% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 4.20 | -93% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 12.64 | -77% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 91.06 | +62% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
BioMarin Pharmaceutical Inc. scores only 4 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. On durability BMRN scores 7.0/10 on the GLS Moat - a middle reading; the Scorecard on the Quote page's Financials tab shows which ten-year lines are steady and which are not.
Returns on capital are moderate - ROIC 5.2%, ROE 5.7%, ROA 4.6% - with debt at 0.11 times equity and a free-cash-flow yield of 6.8%.
BioMarin Pharmaceutical Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Product 100%, Royalty And Other 1% (quarter Q2 FY2026).
Institutional ownership scores 10/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales; the last recorded insider buy was on 10 Sep 2026.
| Piotroski F-score | 4 / 9 | ROIC | 5.2% |
|---|---|---|---|
| GLS Moat | 7.0 / 10 | ROE | 5.7% |
| Debt / equity | 0.11 | ROA | 4.6% |
| Free-cash-flow yield | 6.8% | Payout ratio | 0% |
| Institutions | 10 / 10 | Insiders · Congress | 1 · 5 / 10 |
Wheel Score 59: Fair
A Wheel Score of 59 puts BioMarin Pharmaceutical Inc. in the Fair band - below the 70 the Sunday Scan requires. Value 0/25, Health 9/20, Moat 11/15, Premium 20/20 and Stability 20/20; the weakest part is Value (0/25).
Implied volatility is 44% on the near-the-money contracts 20-60 days out - inside the 35-60% range the Wheel Score pays full marks for: enough premium to be worth selling, not so much that the risk is unpaid. Chain open interest is 35,898 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 2.9M shares a day on a market cap of $10.8B, with a beta of 0.22 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 20 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 0 / 25 | -126% margin of safety | |
| Health | 9 / 20 | Piotroski 4/9 | |
| Moat | 11 / 15 | moat 7.0/10 | |
| Premium | 20 / 20 | implied volatility 44% | |
| Stability | 20 / 20 | 2.9M shares/day, $10.8B cap, beta 0.22 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
BioMarin Pharmaceutical Inc. reports earnings on 26 Oct 2026 (after the close) - inside the 14-day window the Sunday Scan avoids, because a put sold now would carry the report's gap risk.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to BioMarin Pharmaceutical Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals, Inc. | 459.81 | 2,351.92 | +80% | 45Weak | $10.6B |
| IBRX ImmunityBio, Inc. | 10.00 | - | - | 45Weak | $10.6B |
| PCVX Vaxcyte, Inc. | 67.55 | - | - | 45Weak | $10.4B |
| TECH Bio-Techne Corporation | 72.50 | 19.15 | -279% | 62Fair | $11.4B |
| KRYS Krystal Biotech, Inc. | 330.00 | 294.13 | -12% | 61Fair | $9.8B |
| TWST Twist Bioscience Corporation | 148.16 | - | - | 45Weak | $9.8B |
| SMMT Summit Therapeutics Inc. | 15.13 | 0.2422 | -6147% | 32Weak | $12.1B |
| TXG 10x Genomics, Inc. | 73.10 | 19.50 | -275% | 38Weak | $9.5B |
| CAI Caris Life Sciences, Inc. | 31.76 | 18.13 | -75% | 48Weak | $9.0B |
| BBIO BridgeBio Pharma, Inc. | 67.13 | - | - | 45Weak | $13.1B |
| KYMR Kymera Therapeutics, Inc. | 108.14 | 0.2471 | -43656% | 40Weak | $8.9B |
| CYTK Cytokinetics, Incorporated | 63.92 | - | - | 45Weak | $8.9B |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about BMRN
Is BMRN undervalued right now?
No: at 56.05 the stock trades 126% above the GLS average fair value of 24.83 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of BMRN and what does it mean?
BMRN scores 59 out of 100 (Fair). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for BMRN?
24.83 per share as of 16 Oct 2026 - the simple average of the 8 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does BioMarin Pharmaceutical Inc. report earnings next?
The next earnings report is due on 26 Oct 2026 (after the close), 10 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does BMRN have listed options, and how liquid are they?
Yes. The nightly snapshot found 374 listed contracts with 35,898 open interest across all expiries and implied volatility of 44% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.